表单
liquid
浓度
10-20 wt. % in ethanol
折射率
n20/D 1.36
密度
0.792 g/mL at 25 °C
官能团
O-nitroso
nitroso
储存温度
2-8°C
SMILES字符串
CCON=O
InChI
1S/C2H5NO2/c1-2-5-3-4/h2H2,1H3
InChI key
QQZWEECEMNQSTG-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
The reactions of ethyl nitrite solution with human haemoglobin and sperm whale myoglobin were studied.
警示用语：
Danger
危险声明
危险分类
Eye Irrit. 2 - Flam. Liq. 2
储存分类代码
3 - Flammable liquids
WGK
WGK 1
闪点(°F)
59.0 °F - closed cup
闪点(°C)
15 °C - closed cup
个人防护装备
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
法规信息
危险化学品
此项目有
M P Doyle et al.
The Journal of biological chemistry, 256(23), 12399-12404 (1981-12-10)
The reactions of human hemoglobin and sperm whale myoglobin with ethyl nitrite under aerobic conditions have been examined in kinetic detail. Ethyl nitrite converts two equivalents of oxyhemoglobin or oxymyoglobin to their oxidized counterparts with concurrent production of one equivalent
Alessio Baccarani et al.
Journal of reconstructive microsurgery, 23(5), 257-262 (2007-09-19)
Vasospasm leading to thrombosis is a major cause of free flap failure. Flap blood flow may improve by application of vasodilating agents to the pedicle. The purpose of this study is to evaluate the effect of a novel S-nitrosylating agent
Basil M Yurcisin et al.
Annals of surgery, 257(5), 971-977 (2013-01-31)
To determine if reduction in nitric oxide bioactivity contributes to the physiological instability that occurs after brain death and, if so, to also determine in this setting whether administration of a renitrosylating agent could improve systemic physiological status. Organ function
Martin P Moya et al.
Lancet (London, England), 360(9327), 141-143 (2002-07-20)
Inhaled nitric oxide is used to alleviate pulmonary hypertension and hypoxaemia, but generates toxic free radicals and oxides of nitrogen (NO(x)), which can cause rebound-hypoxia and additional pulmonary and other morbidity. To address these problems, we assessed the efficacy of
Takuma Yoshikawa et al.
International journal of pharmaceutics, 583, 119352-119352 (2020-04-24)
Although monoclonal antibodies (mAbs) have revolutionized cancer treatment, their accumulation in solid tumors is limited and requires improvement to enhance therapeutic efficacy. Here we developed a strategy to modify mAb with a donor of nitric oxide (NO) because NO functions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持